 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
The Journal of Neuroscience, December 17, 2003, 23(37):11653-11661
Previous Article | Next Article
Cellular/Molecular
Neuronal Induction of the Immunoproteasome in Huntington's Disease
Miguel Díaz-Hernández,1 * Félix Hernández,1 * Ester Martín-Aparicio,1 Pilar Gómez-Ramos,2 María A. Morán,2 José G. Castaño,3 Isidro Ferrer,4 Jesús Avila,1 andJosé J. Lucas1 1Centro de Biología Molecular "Severo Ochoa", Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Contoblanco, 28049 Madrid, Spain, 2Departamento de Morfología, Facultad de Medicina, UAM, 28029 Madrid, Spain, 3Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC/UAM and Departamento de Bioquímica, Facultad de Medicina, UAM, 28029 Madrid, Spain, and 4Institut de Neuropatologia, Servei d'Anatomia Patologica, Hospital Princeps d'Espanya, Hospitalet de Llobregat, 08907 Barcelona, Spain
Huntington's disease (HD) inclusions are stained with anti-ubiquitin and anti-proteasome antibodies. This, together with proteasome activity studies on transfected cells, suggest that an impairment of the ubiquitin-proteasome system (UPS) may be key in HD pathogenesis. To test whether proteasome activity is impaired in vivo, we performed enzymatic assays for the three peptidase activities of the proteasome in brain extracts from the HD94 conditional mouse model of HD. We found no inhibition of any of the activities, suggesting that if UPS impairment happens in vivo, it is not at the level of the proteasome catalytic core. Intriguingly, the chymotrypsin- and trypsin-like activities increased selectively in the affected and aggregate-containing regions: cortex and striatum. Western blot analysis revealed no difference in total proteasome content whereas an increase in the interferon-inducible subunits of the immunoproteasome, LMP2 and LMP7, was observed. These subunits confer to the proteasome catalytic properties that are optimal for MHC-I peptide presentation. Immunohistochemistry in control mouse brain revealed LMP2 and LMP7 mainly in neurons. Accordingly, their increase in HD94 mice predominantly took place in neurons, and 5% of the ubiquitin-positive cortical aggregates were also LMP2-positive. Ultrastructural analysis of neurons with high level of immunoproteasome subunits revealed signs of neurodegeneration like nuclear indentation or fragmentation and dark cell appearance. The neuronal induction of LMP2 and LMP7 and the associated signs of neurodegeneration were also found in HD postmortem brains. Our results indicate that LMP2 and LMP7 participate in normal neuronal physiology and suggest a role in HD neurodegeneration.
Key words: Huntington's disease; proteasome activity; immunoproteasome inducible subunits: LMP2, LMP7; conditional transgenic mouse model; HD postmortem brain
Received June 18, 2003; revised September 25, 2003; accepted October 22, 2003.
This article has been cited by other articles:
C. J. Maynard, C. Bottcher, Z. Ortega, R. Smith, B. I. Florea, M. Diaz-Hernandez, P. Brundin, H. S. Overkleeft, J.-Y. Li, J. J. Lucas, et al.
Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment
PNAS, August 18, 2009; 106(33): 13986 - 13991.
[Abstract] [Full Text] [PDF]
M.-C. Chiang, H.-M. Chen, H.-L. Lai, H.-W. Chen, S.-Y. Chou, C.-M. Chen, F.-J. Tsai, and Y. Chern
The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system
Hum. Mol. Genet., August 15, 2009; 18(16): 2929 - 2942.
[Abstract] [Full Text] [PDF]
N. P. Dantuma and K. Lindsten
Stressing the ubiquitin/proteasome system
Cardiovasc Res, August 11, 2009; (2009) cvp255v2.
[Abstract] [Full Text] [PDF]
M. Diaz-Hernandez, M. Diez-Zaera, J. Sanchez-Nogueiro, R. Gomez-Villafuertes, J. M. Canals, J. Alberch, M. T. Miras-Portugal, and J. J. Lucas
Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration
FASEB J, June 1, 2009; 23(6): 1893 - 1906.
[Abstract] [Full Text] [PDF]
D. J. Kuhn, S. A. Hunsucker, Q. Chen, P. M. Voorhees, M. Orlowski, and R. Z. Orlowski
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Blood, May 7, 2009; 113(19): 4667 - 4676.
[Abstract] [Full Text] [PDF]
K. Tokui, H. Adachi, M. Waza, M. Katsuno, M. Minamiyama, H. Doi, K. Tanaka, J. Hamazaki, S. Murata, F. Tanaka, et al.
17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse
Hum. Mol. Genet., March 1, 2009; 18(5): 898 - 910.
[Abstract] [Full Text] [PDF]
C. Cheroni, M. Marino, M. Tortarolo, P. Veglianese, S. De Biasi, E. Fontana, L. V. Zuccarello, C. J. Maynard, N. P. Dantuma, and C. Bendotti
Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis
Hum. Mol. Genet., January 1, 2009; 18(1): 82 - 96.
[Abstract] [Full Text] [PDF]
S. Tydlacka, C.-E. Wang, X. Wang, S. Li, and X.-J. Li
Differential Activities of the Ubiquitin-Proteasome System in Neurons versus Glia May Account for the Preferential Accumulation of Misfolded Proteins in Neurons
J. Neurosci., December 3, 2008; 28(49): 13285 - 13295.
[Abstract] [Full Text] [PDF]
R. A. Quintanilla, Y. N. Jin, K. Fuenzalida, M. Bronfman, and G. V. W. Johnson
Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells: POSSIBLE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-{gamma} (PPAR{gamma}) IN THE PATHOGENESIS OF HUNTINGTON DISEASE
J. Biol. Chem., September 12, 2008; 283(37): 25628 - 25637.
[Abstract] [Full Text] [PDF]
C.-E. Wang, S. Tydlacka, A. L. Orr, S.-H. Yang, R. K. Graham, M. R. Hayden, S. Li, A. W.S. Chan, and X.-J. Li
Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease
Hum. Mol. Genet., September 1, 2008; 17(17): 2738 - 2751.
[Abstract] [Full Text] [PDF]
G. Pratt and M. Rechsteiner
Proteasomes Cleave at Multiple Sites within Polyglutamine Tracts: ACTIVATION BY PA28{gamma}(K188E)
J. Biol. Chem., May 9, 2008; 283(19): 12919 - 12925.
[Abstract] [Full Text] [PDF]
J. Wang, C.-E. Wang, A. Orr, S. Tydlacka, S.-H. Li, and X.-J. Li
Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice
J. Cell Biol., March 24, 2008; 180(6): 1177 - 1189.
[Abstract] [Full Text] [PDF]
C. Settembre, A. Fraldi, L. Jahreiss, C. Spampanato, C. Venturi, D. Medina, R. de Pablo, C. Tacchetti, D. C. Rubinsztein, and A. Ballabio
A block of autophagy in lysosomal storage disorders
Hum. Mol. Genet., January 1, 2008; 17(1): 119 - 129.
[Abstract] [Full Text] [PDF]
L. Raffaghello, P. Nozza, F. Morandi, M. Camoriano, X. Wang, M. L. Garre, A. Cama, G. Basso, S. Ferrone, C. Gambini, et al.
Expression and Functional Analysis of Human Leukocyte Antigen Class I Antigen-Processing Machinery in Medulloblastoma
Cancer Res., June 1, 2007; 67(11): 5471 - 5478.
[Abstract] [Full Text] [PDF]
M. Coufal, M. M. Maxwell, D. E. Russel, A. M. Amore, S. M. Altmann, Z. R. Hollingsworth, A. B. Young, D. E. Housman, and A. G. Kazantsev
Discovery of a Novel Small-Molecule Targeting Selective Clearance of Mutant Huntingtin Fragments
J Biomol Screen, April 1, 2007; 12(3): 351 - 360.
[Abstract] [PDF]
Q. Ding, E. Dimayuga, W. R. Markesbery, and J. N. Keller
Proteasome inhibition induces reversible impairments in protein synthesis
FASEB J, June 1, 2006; 20(8): 1055 - 1063.
[Abstract] [Full Text] [PDF]
A. B. James, A.-M. Conway, and B. J. Morris
Regulation of the Neuronal Proteasome by Zif268 (Egr1)
J. Neurosci., February 1, 2006; 26(5): 1624 - 1634.
[Abstract] [Full Text] [PDF]
J. S. Bett, G. M. Goellner, B. Woodman, G. Pratt, M. Rechsteiner, and G. P. Bates
Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REG{gamma} as a therapeutic target
Hum. Mol. Genet., January 1, 2006; 15(1): 33 - 44.
[Abstract] [Full Text] [PDF]
A. G. Valera, M. Diaz-Hernandez, F. HernANdez, Z. Ortega, and J. J. Lucas
The Ubiquitin-Proteasome System in Huntington's Disease
Neuroscientist, December 1, 2005; 11(6): 583 - 594.
[Abstract] [PDF]
M. Perluigi, H. F. Poon, W. Maragos, W. M. Pierce, J. B. Klein, V. Calabrese, C. Cini, C. De Marco, and D. A. Butterfield
Proteomic Analysis of Protein Expression and Oxidative Modification in R6/2 Transgenic Mice: A Model of Huntington Disease
Mol. Cell. Proteomics, December 1, 2005; 4(12): 1849 - 1861.
[Abstract] [Full Text] [PDF]
M. Diaz-Hernandez, J. Torres-Peraza, A. Salvatori-Abarca, M. A. Moran, P. Gomez-Ramos, J. Alberch, and J. J. Lucas
Full Motor Recovery Despite Striatal Neuron Loss and Formation of Irreversible Amyloid-Like Inclusions in a Conditional Mouse Model of Huntington's Disease
J. Neurosci., October 19, 2005; 25(42): 9773 - 9781.
[Abstract] [Full Text] [PDF]
A. B. Bowman, S.-Y. Yoo, N. P. Dantuma, and H. Y. Zoghbi
Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation
Hum. Mol. Genet., March 1, 2005; 14(5): 679 - 691.
[Abstract] [Full Text] [PDF]
T. Shintani and D. J. Klionsky
Autophagy in Health and Disease: A Double-Edged Sword
Science, November 5, 2004; 306(5698): 990 - 995.
[Abstract] [Full Text] [PDF]
M. Diaz-Hernandez, F. Moreno-Herrero, P. Gomez-Ramos, M. A. Moran, I. Ferrer, A. M. Baro, J. Avila, F. Hernandez, and J. J. Lucas
Biochemical, Ultrastructural, and Reversibility Studies on Huntingtin Filaments Isolated from Mouse and Human Brain
J. Neurosci., October 20, 2004; 24(42): 9361 - 9371.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|